The Angiotensin II Receptor Blockers (ARBs) Hypertension market is projected to grow at a CAGR of 3.51%, in terms of value, from USD 7.87 Billion in 2020 to reach USD 10.34 Billion by 2028. This class of drug is used to block angiotensin II effects, and thus prevents the narrowing of blood vessels by angiotensin II action. The Angiotensin II Receptor Blockers (ARBs) Hypertension facilitates widening of blood vessels and reduce blood pressure in an individual. In general, Angiotensin II Receptor Blockers (ARBs) Hypertension are prescribed for patients with intolerance for angiotensin-converting-enzyme inhibitor.

The key factors contributing to the market growth includes increasing incidence of hypertension, chronic kidney diseases, kidney failure in diabetes, and heat failure, across the globe. For instance, according to American Heart Association statistics 2018, more than 103 million individuals in U.S. suffer from high blood pressure However, associated side effects (such as severe dizziness, insomnia, diarrhea, irregular heartbeat, and confusion) are the major hindrance for market growth during 2019-2026.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1156

The pharma and healthcare industry is expected to observe significant growth over the coming years attributed to the increasing incidence of chronic diseases across the globe, growing geriatric patient pool, availability of advanced and minimally invasive surgical and diagnostics procedures, favorable reimbursement scenario, and presence of a robust product pipeline of drugs and therapeutics. In addition, the growing integration of IoT, ML, and AI in medical procedures and equipment along with rapid progress in drug design and development. A combination of innovation and technology has brought about massive changes in the healthcare industry and the rapid adoption of telemedicine, remote consultation, and e-prescription has significantly contributed to the revenue growth of the market.

Further key findings from the report suggest

• Angiotensin II Receptor Blockers (ARBs) Hypertension market is rising at a growth rate of 4.4 percent in Asia Pacific followed by North America and Europe, with 3.4% and 3.2% CAGR respectively. Rising geriatric population in the region and rising obese population in the region will drive the demand for the market during forecast period across all regions.
• Increasing incidence of hypertension cardiovascular diseases in younger population are likely to contribute to the overall market growth.
• Valsartan is the leading Angiotensin II Receptor Blocker in the market with market share of 20.8%. The Valsartan market was valued at USD 1.51 billion and is expected reach USD 1.97 billion by 2026. However, recalls of valsartan during 2018 and 2019, due to cancer concerns is a major challenge for the market growth of this market segment.
• Angiotensin II Receptor Blockers (ARBs) Hypertension is expected to be the fastest growing market segment during forecast period 2019-2026 with a CAGR of 4.5%.
• Asia Pacific is expected to witness a CAGR of 6.5 percent in the forecast period. Emerging markets such China and Japan are likely to witness high growth
• The lack of well-established medical reimbursements for hypertension in various developing regions is likely to hinder the market growth

  Research Methodology:

Reports and Data utilizes a unique approach to research to offer a comprehensive overview of the global Angiotensin II Receptor Blockers (ARBs) Hypertension Market to offer insights into investment opportunities for stakeholders, investors, clients, and businesses to make informed decisions. The report includes SWOT analysis, Porter’s Five Forces analysis, feasibility analysis, and investment return analysis to offer a better understanding of the market scenario.

Inquiry Before Buying @ https://www.reportsanddata.com/inquiry-before-buying/1156

Asia Pacific is expected to lead the market growth over the coming years owing to rapid advancements in the healthcare sector in APAC countries such as India, China, and Japan. North America is anticipated to register the highest market growth over the forecast period attributed to the increasing availability of robust healthcare and clinical settings, legalization of medical marijuana, favorable reimbursement scenario, presence of key market players, and rapid technological advancements in the region.

The growing popularity of over-the-counter medications driving market growth

Growing incidence of acute and chronic diseases and lesser access to advanced medical facilities owing to low disposable income levels are driving the demand for over-the-counter medications. Availability of generic and low-cost alternatives to medical therapies are some other factors playing a major role in driving demand for over-the-counter medications.

Restriction on product launches and RD activities to hamper the market growth

The imposition of strict government regulations and shortage of funds has put a halt on product launches and RD activities and is expected to restrain market growth over the forecast period. In addition, the launch of expensive drugs and therapies and increasing regulations regarding safety and approvals are also hampering the market growth.

  Competitive Landscape:

The global market comprises various market players operating at regional and global levels. These key players are adopting various strategies such as RD investments, license agreements, partnerships, mergers and acquisitions, collaborations, and joint ventures to gain a robust footing in the market.

Top Companies Profiled in the Report:

• AstraZeneca
• Daichii Sankyo
• Novartis
• Abbvie
• Lupin
• Takeda
• Zydus Cadila

  Angiotensin II Receptor Blockers (ARBs) Hypertension Market Segmentation:

Type Outlook:

• Angiotensin II Receptor Blockers (ARBs) Hypertension
• Candesartan
• Eprosartan
• Irbesartan
• Losartan
• Olmesartan
• Telmisartan
• Valsartan

Application Outlook:

• Hypertension
• Cardiovascular risks
• Kidney failure in diabetes
• Chronic kidney diseases

Regional Outlook:

• North America (U.S., Canada, Mexico)
• Europe (Germany, U.K., Italy, France, BENELUX, Rest of Europe)
• Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
• Latin America (Brazil, Rest of LATAM)
• Middle East Africa (Saudi Arabia, U.A.E., South Africa, Rest of the Middle East Africa)

  Frequently asked questions addressed in the report:

• What is the revenue growth rate of the global Angiotensin II Receptor Blockers (ARBs) Hypertension market over the forecast period?
• What are the major factors driving the growth of the Global Angiotensin II Receptor Blockers (ARBs) Hypertension Market?
• What are the key challenges impacting the global Angiotensin II Receptor Blockers (ARBs) Hypertension market growth?
• What are the outcomes of the SWOT Analysis and Porter’s Five Forces Analysis conducted in the report?

Request customization on the report @ https://www.reportsanddata.com/request-customization-form/1156

Thank you for reading our report. For more details please connect with us and our team will ensure the report is customized to meet all the needs of clients. The report also offers a comprehensive regional analysis and specific countries can be included in the report according to the requirements.

Explore Latest Trending Research Reports By Reports and Data:

Peripheral Neuritis Treatment Market @ https://www.biospace.com/article/peripheral-neuritis-treatment-market-overview-by-size-share-growth-trends-and-segmentation-till-2030/

Peripherally Inserted Central Catheters Market @ https://www.biospace.com/article/peripherally-inserted-central-catheters-market-is-expected-to-reach-usd-1-278-3-million-by-2028-at-a-cagr-of-5-30-percent-/

Arthroscopic Devices Market @ https://www.biospace.com/article/arthroscopic-devices-market-is-expected-to-reach-usd-7-866-4-million-by-2028-at-a-cagr-of-6-00-percent-/

Gender Dysphoria Market @ https://www.biospace.com/article/increased-transgender-population-globally-is-expected-to-drive-gender-dysphoria-market-growth-by-2030/

  About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs